Inquire about our medicine compounding services and let us know your health needs and goals we would love to help you however we can!
Women on GLP-1 drugs had an 8% lower risk of obesity-related cancers and a 20% lower risk of death from any cause, compared to those taking #DPP4 inhibitors
When added to a healthy lifestyle, semaglutide has been shown to enhance weight loss, improve insulin sensitivity more quickly, and may help reduce symptoms like irregular periods and high androgen levels
The FDA approved the drug through a new fasttrack review program aimed at shortening approval timelines, saying it reviewed Lillys application in just 50 days
Synergistic Blend Research: To evaluate Cagrilintide in combination with GLP-1 receptor agonists, explore our Semaglutide + Cagrilintide Blend
Until July 1, 2026, Medicare Part D plans could cover GLP-1 drugs only for approved diagnoses such as type 2 diabetes, cardiovascular disease risk reduction, or sleep apnea but not for weight management alone